#BostonStrong

A Shot at Relief

After a successful shoot for the breakout band Macklemore, we are proud to have again worked in the great city of Boston. Biogen Idec trusted our teams to shoot, direct and edit a seven-minute content piece, that was presented on Fenway Park’s Jumbotron during the Boston Red Sox’s opening week.

We could not have been more thrilled to help with the release of their latest blockbuster drug, TECFIDERA™. Our team was honored to craft this pro-mercial piece for such an important cause. The new drug, TECFIDERA™ (dimethyl fumarate), is a new oral therapy recently approved in the United States for the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS), which is the most common form of the disease.

Geoffrey C. Porges, a biotechnology analyst at Sanford Bernstein, said in a note on Monday that he expected global sales to reach $1.7 billion by 2015 and $2.6 billion by 2017.